Journal of personalized medicineOct 26, 2026

Current Understanding and Future Outlook of Semaglutide in Irregular Heartbeats

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 27, 2026

Abstract

A multidimensional approach to arrhythmia management may improve outcomes for individuals with type 2 diabetes mellitus and related conditions.

Cardiac arrhythmias, especially atrial fibrillation, are significant causes of health issues in people with type 2 diabetes, obesity, and heart disease.
Traditional antiarrhythmic drugs have limited effectiveness and potential side effects.
Targeting metabolic, structural, and inflammatory factors may be essential for preventing and managing arrhythmias.
Glucagon-like peptide-1 receptor agonists, particularly semaglutide, are being explored for their possible antiarrhythmic effects beyond blood sugar control.
Current indications for semaglutide in arrhythmia management and future research directions are highlighted.

Simplified

Cardiac arrhythmias, particularly atrial fibrillation (AF), represent a major cause of morbidity and mortality worldwide, especially in individuals with type 2 diabetes mellitus (T2D), obesity, and cardiovascular disease. Traditional antiarrhythmic drugs (AADs) remain the cornerstone of rhythm control, but their efficacy is limited and often accompanied by adverse effects. A multidimensional approach that includes upstream therapy-targeting metabolic, structural and inflammatory substrates-has therefore emerged as a critical strategy in arrhythmia prevention and management. Among novel therapeutic agents, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, are gaining attention for their potential antiarrhythmic properties beyond glycaemic control. This review discusses multidimensional arrhythmia management, current indications for semaglutide, and future perspectives on its role as a potential upstream antiarrhythmic therapy.

Full Text

Full text is available at the source.

View Full Text ↗

Current Understanding and Future Outlook of Semaglutide in Irregular Heartbeats

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief